
Studies on aducanumab were halted earlier this year because the drug didn't appear to be effective. But the new results suggest it's effective at a high dose, the Associated Press reported.
Studies on aducanumab were halted earlier this year because the drug didn't appear to be effective. But the new results suggest it's effective at a high dose, the Associated Press reported.